Showing results (201-210 of 213) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|May 31, 2024
Recent advances and impending challenges for the radiopharmaceutical sciences in oncologySuzanne E Lapi, Peter J H Scott, Andrew M Scott, et al.
Atherosclerosis|June 6, 2016
HDL mimetic CER-001 targets atherosclerotic plaques in patientsKang He Zheng, Fleur M van der Valk, Loek P Smits, et al.
BMC Cardiovascular Disorders|February 14, 2022
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging studyAshutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, et al.
Theranostics|December 18, 2018
Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation stateAlessandro Villa, Barbara Klein, Bieneke Janssen, et al.
Advanced Drug Delivery Reviews|November 7, 2022
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micellesCristianne J F Rijcken, Federica De Lorenzi, Ilaria Biancacci, et al.
Cancer Research|May 11, 2017
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung CancerSai Kiran Sharma, Jacob Pourat, Dalya Abdel-Atti, et al.
Oncotarget|June 7, 2018
89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-bindingEmilie M J van Brummelen, Marc C Huisman, Linda J de Wit-van der Veen, et al.
Scientific Reports|April 28, 2018
Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activationBieneke Janssen, Danielle J Vugts, Shane M Wilkinson, et al.
NPJ Breast Cancer|January 6, 2024
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)Magdalena Mileva, Elisabeth G E de Vries, Thomas Guiot, et al.
Nature Cancer|May 1, 2026
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trialIgnacio Melero, Bernhard Reis, Corinne Rusterholz, et al.
Pageof 22